KineMed/Merck Sign Cardiovascular Research Collaboration Pact Potentially Worth $75.5 Mil.
This article was originally published in The Pink Sheet Daily
Executive Summary
KineMed will use its proprietary reverse cholesterol transport technology to evaluate up to 10 investigational compounds provided by Merck.